Indian CDMO Firms Lead Pharma Sector with Strong Growth Prospects

The pharmaceutical and healthcare sectors in India have shown impressive gains over the last six months, outpacing broader market indices by roughly 20 percent. Among the various subsectors, contract development and manufacturing organisations, commonly known as CDMOs, have stood out with exceptional returns, significantly surpassing their healthcare and pharma counterparts.

Laurus Labs has been a leading force in this space, delivering a remarkable 90 percent return during this period. The top five publicly traded firms, all deriving at least 40 percent of their revenue from CDMO activities, have collectively averaged returns exceeding 60 percent. This robust performance reflects a growing trend among global pharmaceutical and biotech firms to outsource more of their manufacturing and development work, as well as a strategic shift in supply chains favoring Indian CDMO providers.

Industry analysts forecast that this growth trajectory will persist as the demand for biologics continues to climb. The expanding pipeline of biosimilar drugs and increasing interest in peptide-based therapies also contribute to a positive outlook. However, the strong valuations of these companies, trading at an average of 66 times projected earnings for fiscal year 2027, indicate that some of this growth potential is already priced into the market.

During the June quarter, the broader pharmaceutical sector showed mixed results. While domestic formulation sales remained solid, challenges in the US generics market limited growth. In contrast, CDMO players reported robust performance, with several leading companies achieving over 20 percent revenue growth and a 60 percent increase in operating profits.

According to India Ratings and Research, the CDMO sector maintained double-digit year-on-year revenue growth in the first quarter of fiscal 2027 despite some firms experiencing temporary setbacks such as customer inventory reductions and product discontinuations. The agency expects continued momentum driven by strong demand from global innovators, better capacity utilization, and ongoing investments in expanding manufacturing facilities.

As newly commissioned production lines come online, companies are positioned to benefit from economies of scale and improved asset returns. The next phase of growth will depend heavily on how well these firms execute their business plans and commercialize previous investments.

Currently, Indian CDMOs generate approximately $3 to $3.5 billion in revenue, which represents around 2 to 3 percent of the global CDMO market valued at $140 to $145 billion. Projections suggest this figure could increase sevenfold to reach $22 to $25 billion by 2035, underscoring the vast opportunity ahead.

Global supply chain diversification efforts are expected to favor Indian companies. Recent US policy moves, including the inclusion of WuXi AppTec on the Pentagon’s Section 1260H list and the implementation of the BIOSECURE Act, have accelerated the trend toward sourcing from alternative CDMOs. Research from Deven Choksey highlights that US pharmaceutical firms are increasingly turning to Indian CDMOs for their regulatory compliance, high-quality manufacturing standards, and cost advantages.

Brokerages note that these developments should lead to a surge in requests for proposals, feasibility studies, and customer interactions in the near term. Divi’s Laboratories remains the preferred pick among many analysts, including Macquarie and JP Morgan, for its strong industry positioning and attractive margins.

Macquarie Research also points to Novo Nordisk’s recent strategic decision to outsource peptide drug manufacturing as a significant endorsement of the CDMO sector’s growth potential. The Danish pharmaceutical giant, known for its GLP-1 weight-loss medications, is shifting production of complex peptide-based active ingredients to external CDMO partners, reinforcing demand in this niche.

Way2Wealth Brokers maintain an accumulate rating on Laurus Labs and Sai Life Sciences, citing factors such as rising global outsourcing, capacity expansions, and unique technological capabilities. While Divi’s Laboratories continues to lead with superior margins, and Syngene International provides stability, both trade at high valuations. Meanwhile, companies like Piramal Pharma and Akums Drugs and Pharmaceuticals are beginning to show signs of margin improvement, offering potential upside for investors.

In summary, Indian CDMO companies are carving out a significant role in the global pharmaceutical manufacturing landscape. Their ability to offer high-quality, cost-effective, and compliant services is attracting increasing interest from multinational pharmaceutical firms. With ongoing capacity enhancements and supportive global trends, the sector is well-positioned for sustained growth in the coming years.